22 Immunohistochemical expression of cytosolic thymidine kinase in patients with breast carcinoma

Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas

Volumn 1, Issue , 2002, Pages 463-469

  He, Qimin ^a   Mao, Yongrong ^a   Wu, Jianping ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649359708     PISSN: 18745784     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5784(04)80056-4     Document Type: Chapter

References (24)

1. ASCO. Recommendations of the American Society of Clinical Oncology. A patient's guide: Understanding tumor markers for breast and colorectal cancers. Am. Soc. Clin. Oncol. (2002) 3-16
2. Aziz S., Pervez S., Khan S., Siddiqui. T., Kayani N., Israr M., and Rahbar M. Case control study of novel prognostic markers and diseases outcome pregnancy/lactation-associated breast carcinoma. Pathol. Res. Pract. 199 (2003) 15-21
3. Beenken S.W., and Bland K.I. Biomarkers for breast cancer. Minerva Chir. 57 (2002) 437-448
4. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br. J. Cancer 88 (2003) 406-412
5. He Q., Skog S., and Tribukait B. Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumors. Cell Prolif. 24 (1991) 3-14
6. He Q., Wang N., Skog S., Eriksson S., and Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Ear. J. Cell Biol. 70 (1996) 117-124
7. He Q., Zou L., Zhang P.G., Lui J.X., Skog S., and Fornander T. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TKl antibody. Int. J. Biol. Marker 15 (2000) 139-146
8. Accepted by. He Q., Mao R.Y., Wu J.P., Eriksson S., and Skog S. Cytosolic thymidine kinase (TK1) as a marker for cell proliferation in malignant tissues. AACC Annual Meeting D-35 (2003)
9. Kato T., Kameoka S., Kimura T., Nishikawa T., and Kobayashi M. C-erb-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res. 22 (2002) 1097-1103
10. Kauffman M.G., and Kelly T.J. Cell cycle regulation of thymidine kinase: Residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol. Cell. Biol. 11 (1991) 2538-2589
11. Kuroiwa N., Nakayama M., Fufuda T., Fufui H., Ohwada H., Hiwasa T., and Fujimura S. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibody raised against recombinant human thymidine kinase. J. Immunol. Methods 255 (2001) 1-11
12. Lakhani S.R., and Ashworth A. Microarray and histopathological analysis of tumours: The future and the past. Nat. Rev. Cancer 2 (2001) 15-17
13. Mao Y.R., Wu J.P., Wang N., He J.X., Wu C.J., He Q., and Skog S. A comparison study: Immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest. 20 (2002) 922-931
14. Molino A., Pedersini R., Micciolo R., Frisinghelli M., Giovannini M., Pavarana M., Nortilli R., Santo A., Manno P., Padovani M., Piubello Q., and Cetto G.L. Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients. Appl. Immunohistochem. Mol. Morphol. 10 (2002) 304-309
15. Pegram M., and Slamon D. Biological relation for Her/neu (c-erbB2) as a target for monoclonal antibody therapy. Sim. Oncol. 27 Suppl. 9 (2000) 13-19
16. Perou C.M., Sørlie T., Elsen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.B., Ross D.T., Johnsen H., Akslen L.A., Fluge Ø., Pergamenschlkov A., Williams C., Zhu S.X., Lonning P.E., Børresen-Dale A.-L., Brown P.O., and Botstein D. Molecular portraits of human breast tumors. Nature 406 (2000) 141-752
17. Sherley J.L., and Kelly T.J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. 26 (1988) 8350-8358
18. Trihia H., Murray S., Price K., Gelber R.D., Golouh R., Goldhirsh A., Coates A.S., Collins J., Castiglione-Gertsch M., and Gusterson B.A. Ki-67 expression in breast carcinoma. Cancer 97 (2003) 1321-1331
19. Voeller D.M., Parr A., and Allegra C.J. Development of human anti-thymidine kinase antibodies. Anti-Cancer Drugs 72 (2001) 555-559
20. Wang N., He Q., Skog S., Eriksson S., and Tribukait B. Investigation on cell proliferation with a new antibody against thymidine kinase 1. Analyt. Cell. Pathol. 23 (2001) 11-19
21. Wu J.P., Mao Y.R., He L.X., Wang N., Wu C.J., He Q., and Skog S. Comparison study on the expression of cytosolic thymidine kinase and proliferating cell nuclear antigen in colorectal carcinoma. Anticancer Res. 6 (2000) 4867-4872
22. in press. Wu C.J., Yang R.J., Zhou J., Bao S., Zou L., Zhang P.G., Mao Y.R., Wu J.P., and He Q. Production and characterization of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J. Immuno. Method. 277 (2003) 157-168
23. Zhang F., Li H., Pendleton A.R., Robison J.G., Monson K.O., Murray B.K., and O'Neill K.L. Thymidine kinase 1 immunoassay: A potential maker for breast cancer. Cancer Detect. Prev. 25 (2001) 8-15
24. Zou L., Zhang P.G., Zou S., Li Y., and He Q. The half-life of cytosolic thymidine kinase in serum by ECL dot blot: A potential marker for monitoring the response to surgery of patients with gastric cance. Int. J. Biolog. Marker 17 (2002) 135-140